治疗恶性胶质瘤新药---卡莫司汀晶片植入物（Gliadel）

Glioblastoma, which has the characteristics of high incidence, high recurrence rate, high mortality and low cure rate, is the most common and most malignant primary brain tumor in adults. (Gliadel) has been marketed in the United States for the treatment of adult patients with newly diagnosed high-grade malignant glioma as an auxiliary means to surgery and radiotherapy. Today we will take a detailed look at the new drug for the treatment of malignant glioma---carmustine chip implant (Gliadel).

Carmustine chip implant (Gliadel) is the world's only new drug for the treatment of malignant glioma. It was launched in the United States in 1996. It is an alkylating drug. The trial showed that 820 patients were divided into the implant group and the standard group. Analysis of the entire group showed that the HR of PFS in the implant group vs. the standard group was 0.81; the median PFS in the implant group was 12.0 months, and the median PFS in the standard group was 10 months. It was confirmed that the drug combined with maximum safe resection + standard radiotherapy and chemotherapy may represent a promising first-line treatment option. Nausea, vomiting, cerebral edema, weakness, constipation, abnormal wound healing and depression are the main side effects of carmustine chip implant (Gliadel). Urinary tract infection, abnormal wound healing and fever are the most common side effects of recurrent high-grade malignant glioma.

In terms of usage and dosage, carmustine chip implant (Gliadel) is only for intralesional use. There is 7.7 mg of carmustine in each carmustine wafer implant (Gliadel), and when eight implants are placed in the tumor resection cavity, the dose is 61.6 mg. If the size and shape of the resection cavity allows, it is recommended to place up to 8 implants. It should be noted that it is contraindicated in patients who are allergic to the active substance carmustine or any of the excipients of GLIADEL Implant.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: